Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03542435 · ClinicalTrials.gov registry record · Phase 1
Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023
A Phase 1 study, sponsored by Promentis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03542435 is a Phase 1 study that has completed, run by Promentis Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT03542435, a Phase 1 study, has completed, sponsored by Promentis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multiple ascending dose study conducted at one study center in the United States. Safety and tolerability will be assessed throughout the study and serial blood samples and urine samples will be collected for the safety and pharmacokinetic assessment of SXC-2023.
Interventions
- DRUG Placebo
- DRUG SXC-2023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2018-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03542435
The ClinicalTrials.gov registry entry for NCT03542435 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Promentis Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03542435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03542435 about?
NCT03542435 is a clinical study titled "Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023". This is a randomized, double-blind, placebo-controlled, multiple ascending dose study conducted at one study center in the United States. Safety and tolerability will be assessed throughout the study and serial blood samples and urine samples will be collected for the safety and pharmacokinetic asse...
What is the current status of trial NCT03542435?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-04-26. Estimated completion is 2018-09-10.
What interventions are being tested in trial NCT03542435?
The interventions under investigation include: Placebo (DRUG), SXC-2023 (DRUG).
Who is sponsoring clinical trial NCT03542435?
This trial is sponsored by Promentis Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.